OpenLB
Open Library of Bioscience
Advanced Search
Rheumatology international
10, 2023;43 (10): 1871-1883.

Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.

Panagiotis Athanassiou, Dimitrios Psaltis, Athanasios Georgiadis, Gkikas Katsifis, Athina Theodoridou, Souzana Gazi, Prodromos Sidiropoulos, Maria G Tektonidou, Andreas Bounas, Anna Kandyli, Periklis Vounotrypidis, Grigorios T Sakellariou, Dimitrios Vassilopoulos, Zhiping Huang, Evangelia Petrikkou, Dimitrios Boumpas
Author Information
  1. Panagiotis Athanassiou: Rheumatology Department, Aghios Pavlos" General Hospital of Thessaloniki, Thessaloniki, Greece.
  2. Dimitrios Psaltis: Private Practice, Serres, Greece.
  3. Athanasios Georgiadis: Private Practice, Ioannina, Greece.
  4. Gkikas Katsifis: Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece.
  5. Athina Theodoridou: Private Practice, Thessaloniki, Greece.
  6. Souzana Gazi: Rheumatology Unit, "KAT" Regional General Hospital, Athens, Greece.
  7. Prodromos Sidiropoulos: Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece.
  8. Maria G Tektonidou: Rheumatology Unit, 1st Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Joint Rheumatology Program, Laiko Hospital, Athens, Greece.
  9. Andreas Bounas: "OLYMPION", General Clinic of Patra, Patra, Greece.
  10. Anna Kandyli: Private Practice, Athens, Greece.
  11. Periklis Vounotrypidis: Private Practice, Thessaloniki, Greece.
  12. Grigorios T Sakellariou: Private Practice, Thessaloniki, Greece.
  13. Dimitrios Vassilopoulos: 2nd University Department of Internal Medicine, General Hospital of Athens "Ippokrateion", Athens, Greece.
  14. Zhiping Huang: Epidemiology, Biostatistics and Research Decision Sciences (BARDS), Merck & Co., Inc., Kenilworth, NJ, 07033, USA.
  15. Evangelia Petrikkou: MSD Pharmaceutical, Industrial and Commercial S.A, Athens, Medical Affairs, MSD Greece, 63 Agiou Dimitriou Street, 17456, Alimos, Greece. evangelia.petrikkou1@merck.com. ORCID
  16. Dimitrios Boumpas: Rheumatology and Clinical Immunology, 4th Department of Internal Medicine, "Attikon" University Hospital, Rimini 1, 124 62, Athens, Greece.
PMID: 37402886 DOI: 10.1007/s00296-023-05376-5

Abstract

The impact of golimumab (GLM) on remission or low disease activity (LDA) was evaluated in patients with moderate-to-severe rheumatoid arthritis (RA), progressive psoriatic arthritis (PsA), or severe axial spondyloarthritis (axSpA), who failed previous treatment for their rheumatic disease with one initial tumor necrosis factor α inhibitor (TNFi). This is a multicenter, prospective, real-world observational 18-month study, conducted in Greece. The primary endpoint, assessed at 6 months, included the proportion of patients attaining LDA and/or remission (Disease Activity Score for 28 joints based on C-reactive protein [DAS28-CRP] ≤ 3.2), minimal disease activity (MDA; MDA criteria), and moderate disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] score 4-7), respectively. Other endpoints evaluated the persistence to GLM treatment and its impact on patients' work productivity (Work Productivity and Activity Impairment [WPAI] instrument) and quality of life (QoL; EuroQoL5 dimensions 3 levels [EQ-5D-3L] questionnaire). Descriptive statistics, the Wilcoxon signed-rank test, and Kaplan-Meier method were used for analyses. At 6 months, LDA was achieved by 46.4% of patients with RA, MDA by 57.1% of patients with PsA, and BASDAI 4-7 by 24.1% of patients with axSpA. For all study patients, persistence rates on GLM were high (85.1-93.7%) over 18 months; all WPAI domain scores and the EQ-5D-3L index score improved significantly (p < 0.001) from baseline to 18 months. GLM treatment was effective in patients with RA, PsA, or axSpA who had failed previous treatment with one TNFi and led to significant WPAI and QoL improvements. Persistence rates were high. Trial registration number and date of registration: As per the local regulations the study has been registered at the national registry for non-interventional studies https://www.dilon.sfee.gr/studiesp_d.php?meleti_id=MK8259-6995 .

Keywords

Axial spondyloarthritis Disease activity Golimumab Psoriatic arthritis Quality of life Rheumatoid arthritis

References

  1. Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH (2018) Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open 8(6):e021082. https://doi.org/10.1136/bmjopen-2017-021082
  2. Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8 [DOI: 10.1016/S0140-6736(16)30173-8]
  3. Veale DJ, Fearon U (2018) The pathogenesis of psoriatic arthritis. Lancet 391(10136):2273–2284. https://doi.org/10.1016/S0140-6736(18)30830-4 [DOI: 10.1016/S0140-6736(18)30830-4]
  4. Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73–84. https://doi.org/10.1016/S0140-6736(16)31591-4 [DOI: 10.1016/S0140-6736(16)31591-4]
  5. Michelsen B, Fiane R, Diamantopoulos AP et al (2015) A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One 10(4): e0123582. https://doi.org/10.1371/journal.pone.0123582
  6. Smolen JS, Landewé RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685–699. https://doi.org/10.1136/annrheumdis-2019-216655 [DOI: 10.1136/annrheumdis-2019-216655]
  7. Gossec L, Baraliakos X, Kerschbaumer A et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700–712. https://doi.org/10.1136/annrheumdis-2020-217159 [DOI: 10.1136/annrheumdis-2020-217159]
  8. van der Heijde D, Ramiro S, Landewé R et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978–991. https://doi.org/10.1136/annrheumdis-2016-210770 [DOI: 10.1136/annrheumdis-2016-210770]
  9. Rubbert-Roth A, Szabó MZ, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P (2019) Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. Autoimmun Rev 18(12):102398. https://doi.org/10.1016/j.autrev.2019.102398
  10. Alten R, Conaghan PG, Strand V et al (2019) Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study. Clin Rheumatol 38(6):1615–1626. https://doi.org/10.1007/s10067-019-04446-z [DOI: 10.1007/s10067-019-04446-z]
  11. Juanola X, Ramos MJM, Belzunegui JM, Fernández-Carballido C, Gratacós J (2022) Treatment failure in axial spondyloarthritis: insights for a standardized definition. Adv Ther 39(4):1490–1501. https://doi.org/10.1007/s12325-022-02064-x [DOI: 10.1007/s12325-022-02064-x]
  12. Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J (2017) Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the corrona RA registry. Rheumatol Ther 4(2):489–502. https://doi.org/10.1007/s40744-017-0078-y [DOI: 10.1007/s40744-017-0078-y]
  13. Stober C, Ye W, Guruparan T, Htut E, Clunie G, Jadon D (2018) Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. Rheumatology (Oxford) 57(1):158–163. https://doi.org/10.1093/rheumatology/kex387 [DOI: 10.1093/rheumatology/kex387]
  14. Manica SR, Sepriano A, Pimentel-Santos F et al (2020) Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant? Arthritis Res Ther 22(1):195. https://doi.org/10.1186/s13075-020-02288-8 [DOI: 10.1186/s13075-020-02288-8]
  15. Choquette D, Bessette L, Alemao E et al (2019) Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry. Arthritis Res Ther 21(1):138. https://doi.org/10.1186/s13075-019-1917-8 [DOI: 10.1186/s13075-019-1917-8]
  16. Gossec L, Siebert S, Bergmans P et al (2021) Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann Rheum Dis 81(6):823–830. https://doi.org/10.1136/annrheumdis-2021-221640 [DOI: 10.1136/annrheumdis-2021-221640]
  17. Bekele DI, Cheng E, Reimold A et al (2022) Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis. Rheumatol Int 42(11):1925–1937. https://doi.org/10.1007/s00296-021-05024-w [DOI: 10.1007/s00296-021-05024-w]
  18. European Medicines Agency. Simponi Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf . Accessed 06 June 2023
  19. Flipo RM, Tubach F, Goupille P et al (2021) Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study. Clin Exp Rheumatol 39(3):537–545. https://doi.org/10.55563/clinexprheumatol/zizo0l [DOI: 10.55563/clinexprheumatol/zizo0l]
  20. Alegre-Sancho JJ, Juanola X, Rodríguez-Heredia JM et al (2021) Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: a retrospective study. Medicine (Baltimore) 100(13):e25223. https://doi.org/10.1097/MD.0000000000025223
  21. Iannone F, Favalli EG, Caporali R et al (2021) Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine 88(1):105062. https://doi.org/10.1016/j.jbspin.2020.07.011
  22. Akar S, Kalyoncu U, Dalkilic E et al (2021) GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey. Immunotherapy 13(10):841–850. https://doi.org/10.2217/imt-2020-0296 [DOI: 10.2217/imt-2020-0296]
  23. Krüger K, Burmester GR, Wassenberg S, Thomas MH (2020) Golimumab as the first-, second-, or at least third-line biologic agent in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis: post hoc analysis of a noninterventional study in Germany. Rheumatol Ther 7(2):371–382. https://doi.org/10.1007/s40744-020-00204-9 [DOI: 10.1007/s40744-020-00204-9]
  24. Michelsen B, Sexton J, Wierød A, Bakland G, Rødevand E, Krøll F, Kvien TK (2020) Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study. Semin Arthritis Rheum 50(1):12–16. https://doi.org/10.1016/j.semarthrit.2019.07.003 [DOI: 10.1016/j.semarthrit.2019.07.003]
  25. D'Angelo S, Tirri E, Giardino AM et al (2022) Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study. J Clin Med 11(14):4178. https://doi.org/10.3390/jcm11144178
  26. Anderson J, Caplan L, Yazdany J et al (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64(5):640–647. https://doi.org/10.1002/acr.21649 [DOI: 10.1002/acr.21649]
  27. Mease PJ, Coates LC (2018) Considerations for the definition of remission criteria in psoriatic arthritis. Semin Arthritis Rheum 47(6):786–796. https://doi.org/10.1016/j.semarthrit.2017.10.021 [DOI: 10.1016/j.semarthrit.2017.10.021]
  28. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291 [PMID: 7699630]
  29. Fransen J, van Riel PL (2005) The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 23(5 Suppl 39):S93–S99 [PMID: 16273792]
  30. Machado P, Landewé R, Lie E et al (2011) Assessment of SpondyloArthritis international Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70(1):47–53. https://doi.org/10.1136/ard.2010.138594
  31. Rudwaleit M, Listing J, Brandt J et al (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 63:665–670. https://doi.org/10.1136/ard.2003.016386 [DOI: 10.1136/ard.2003.016386]
  32. Kiltz U, van der Heiijde D, Boonen A et al (2015) Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 74(5):830–835. https://doi.org/10.1136/annrheumdis-2013-203967 [DOI: 10.1136/annrheumdis-2013-203967]
  33. Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353–365. https://doi.org/10.2165/00019053-199304050-00006 [DOI: 10.2165/00019053-199304050-00006]
  34. Smolen JS, Aletaha D (2015) Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 11(5):276–289. https://doi.org/10.1038/nrrheum.2015.8 [DOI: 10.1038/nrrheum.2015.8]
  35. Rahman P, Zummer M, Bessette L, et al (2017) Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry. BMJ Open 7(8):e016619. https://doi.org/10.1136/bmjopen-2017-016619
  36. Krueger K, Remstedt S, Thiele A, Hohenberger S (2020) Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany. J Comp Eff Res 9(12):891–902. https://doi.org/10.2217/cer-2020-0092 [DOI: 10.2217/cer-2020-0092]
  37. Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH (2019) Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. Rheumatol Int 39(1):131–140. https://doi.org/10.1007/s00296-018-4180-4 [DOI: 10.1007/s00296-018-4180-4]

MeSH Term

Humans
Adult
Arthritis, Psoriatic
Quality of Life
Prospective Studies
Greece
Treatment Outcome
Arthritis, Rheumatoid
Immunologic Factors
Axial Spondyloarthritis
Antirheumatic Agents

Chemicals

golimumab
Immunologic Factors
Antirheumatic Agents
Observational Study Multicenter Study Journal Article
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0patientsarthritisGLMdiseaseactivitytreatmentstudyLDARAPsAspondyloarthritisaxSpATNFiDiseaseActivityMDAimpactgolimumabremissionevaluatedrheumatoidpsoriaticaxialfailedpreviousoneinitialprospectiveobservational6monthsscore4-7persistencelifeQoL1%rateshigh18 monthsWPAIlowmoderate-to-severeprogressivesevererheumatictumornecrosisfactorαinhibitormulticenterreal-world18-monthconductedGreeceprimaryendpointassessedincludedproportionattainingand/orScore28jointsbasedC-reactiveprotein[DAS28-CRP] ≤ 32minimalcriteriamoderateBathAnkylosingSpondylitisIndex[BASDAI]respectivelyendpointspatients'workproductivityWorkProductivityImpairment[WPAI]instrumentqualityEuroQoL5dimensions3levels[EQ-5D-3L]questionnaireDescriptivestatisticsWilcoxonsigned-ranktestKaplan-Meiermethodusedanalysesachieved464%57BASDAI24851-937%domainscoresEQ-5D-3Lindeximprovedsignificantlyp < 0001baselineeffectiveledsignificantimprovementsPersistenceTrialregistrationnumberdateregistration:perlocalregulationsregisterednationalregistrynon-interventionalstudieshttps://wwwdilonsfeegr/studiesp_dphp?meleti_id=MK8259-6995Real-worldeffectivenessadultinadequateresponsetherapyGreece:GO-BEYONDAxialGolimumabPsoriaticQualityRheumatoid

Similar Articles

Cited By